Programmed Cell Death 1 Ligand 1 (PD-L1)
Human Recombinant PD-L1 Protein
| Name |
Programmed cell death 1 ligand 1 (PD-L1) |
| Alternative Names |
CD274 protein, B7-H protein, B7H1 protein, PDCD1L1 protein, PDCD1LG1 protein |
| Catalog # |
P1220 |
| Uniprot ID |
Q9NZQ7.1 |
| Description |
C-terminal His-tagged PD-L1 fusion protein, derived from mammalian expression system, expressed by transfected HEK293 cells |
| Purity |
> 90%, analyzed by SDS-PAGE |
| Species |
Human |
| MW |
Around 28.3 kDa |
| Endotoxin Level |
< 1EU/μg, analyzed by LAL assay |
| Storage |
Lyophilized powder 4°C valid for 3 years, -20°C after rehydration valid for 1 year. Avoid freeze / thaw cycles. |
| Transportation |
Ordinarily lyophilized powder, transported at low temperature |
| SDS-PAGE |
 |
Introduction of programmed cell death 1 ligand 1 (PD-L1)
Programmed cell death 1 ligand 1 (PD-L1), also known as PDCD1, also known as B7-H1 or CD274, which is a transmembrane glycoprotein of B7 family of immune regulatory molecules.
It has been identified as a ligand for PD-1 and plays a role in immune regulation. Mature PD-L1 is composed of an extracellular domain (ECD) of 220 amino acids, two immunoglobulin domains, one 21aa transmembrane domain and one 31aa cytoplasmic domain. In ECD, human PD-L1 and mouse PD-L1 share 73% of the sequence identity.
By collaborating with PD-1, PD-L1 can inhibit the production of cytokines and the proliferation of T cells. Therefore, promoting the growth of tumor by increasing the apoptosis of specific T cells, which may also contribute to the immune evasion of cancer. The blocking of the connection between PD-1 and PD-L1 by monoclonal antibodies has been proven to be an effective anti-tumor therapy, which maintains the activity of the immune response and attacks carcinogenic cells that will escape from recognition of immune cells.
References
[1] SabrinaCeeraz. et al. Trends in Immunology. Science Direct, 2013, 34(11):556-563.
[2] Mazanet, M. et al. B7-H1 ls Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis. The Journal of Immunology, 2002, 169(7):3581.
[3] lwai, Y. et al. nvolvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. PNAS, 2002, 99 (19):12293-7.
Related Products
